A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Symptomatic Healthcare Professionals During the COVID-19...

Overview

Journal Vaccines (Basel)

Date 2023 Jan 21

PMID 36679920

Authors

Pawel Zapolnik

Wojciech Kmiecik

Anna Nowakowska

Lukasz Jerzy Krzych

Henryk Szymanski

Lidia Stopyra

Teresa Jackowska

Dorota Darmochwal-Kolarz

Artur Mazur

Hanna Czajka

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) was the predominant cause of death from a single infectious agent worldwide before the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Although TB vaccines have been successfully used for about 100 years, their full effect is still unknown. In previous studies, a reduced incidence and mortality from a coronavirus disease in TB-vaccinated populations were reported. In this article, we present the secondary analysis of a randomised controlled trial, reporting the results of a serological assessment evaluating the effect of the Bacillus Calmette-Guérin (BCG) vaccine on SARS-CoV-2. Participants-healthcare workers-were assessed 1-2 and 8 months after the second dose of the coronavirus disease 2019 (COVID-19) vaccine. We found no associations between antibody concentration, BCG revaccination, and additional characteristics, such as age, gender, or Body Mass Index. The effect of BCG vaccination on the immunological response against SARS-CoV-2 requires further research.

Citing Articles

Non-specific protection against severe COVID-19 associated to typhoid fever and DTP vaccination.

Juste R, Vrotsou K, Mateo-Abad M, Gutierrez-Stampa M, Rotaeche R, Vergara I Heliyon. 2024; 10(9):e29935.

PMID: 38707311 PMC: 11068531. DOI: 10.1016/j.heliyon.2024.e29935.

Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.

Chen K, Zhang L, Fang Z, Li J, Li C, Song W Front Immunol. 2023; 14:1294288.

PMID: 38090587 PMC: 10711607. DOI: 10.3389/fimmu.2023.1294288.

Interpreting the Results of Trials of BCG Vaccination for Protection Against COVID-19.

Noble C, Messina N, Pittet L, Curtis N J Infect Dis. 2023; 228(10):1467-1478.

PMID: 37558650 PMC: 10640778. DOI: 10.1093/infdis/jiad316.

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.

Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C Front Immunol. 2023; 14:1172851.

PMID: 37465688 PMC: 10352084. DOI: 10.3389/fimmu.2023.1172851.

Trained Immunity, BCG and SARS-CoV-2 General Outline and Possible Management in COVID-19.

Zapolnik P, Kmiecik W, Mazur A, Czajka H Int J Mol Sci. 2023; 24(4).

PMID: 36834629 PMC: 9961109. DOI: 10.3390/ijms24043218.

References

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Garly M, Martins C, Bale C, Balde M, Hedegaard K, Gustafson P . BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?. Vaccine. 2003; 21(21-22):2782-90. DOI: 10.1016/s0264-410x(03)00181-6. View

Noval Rivas M, Ebinger J, Wu M, Sun N, Braun J, Sobhani K . BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest. 2020; 131(2). PMC: 7810479. DOI: 10.1172/JCI145157. View

Rashidzadeh H, Danafar H, Rahimi H, Mozafari F, Salehiabar M, Rahmati M . Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives. Nanomedicine (Lond). 2021; 16(6):497-516. PMC: 7938776. DOI: 10.2217/nnm-2020-0441. View

Czajka H, Zapolnik P, Krzych L, Kmiecik W, Stopyra L, Nowakowska A . A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19.... Vaccines (Basel). 2022; 10(2). PMC: 8879775. DOI: 10.3390/vaccines10020314. View

Dionato F, Jalalizadeh M, Buosi K, Visacri M, Col L, Giacomelli C . BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial. Vaccine. 2022; 40(32):4603-4608. PMC: 9212358. DOI: 10.1016/j.vaccine.2022.06.039. View

Gvozdjakova A, Klauco F, Kucharska J, Sumbalova Z . Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?. Bratisl Lek Listy. 2020; 121(11):775-778. DOI: 10.4149/BLL_2020_126. View

Uysal E, Gumus S, Bektore B, Bozkurt H, Gozalan A . Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J Med Virol. 2021; 94(3):1060-1066. PMC: 8661654. DOI: 10.1002/jmv.27420. View

Moorlag S, Taks E, Ten Doesschate T, van der Vaart T, Janssen A, Muller L . Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic. Clin Infect Dis. 2022; 75(1):e938-e946. PMC: 8903481. DOI: 10.1093/cid/ciac182. View

10.

Moreno Fernandez-Ayala D, Navas P, Lopez-Lluch G . Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol. 2020; 142:111147. PMC: 7648491. DOI: 10.1016/j.exger.2020.111147. View

11.

Faustman D, Lee A, Hostetter E, Aristarkhova A, Ng N, Shpilsky G . Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med. 2022; 3(9):100728. PMC: 9376308. DOI: 10.1016/j.xcrm.2022.100728. View

12.

Khanum I, Kumar L, Awan S, Jamil B . Severity of COVID-19 in bacillus Calmette-Guérin vaccinated population. Clin Exp Vaccine Res. 2021; 10(3):276-281. PMC: 8511583. DOI: 10.7774/cevr.2021.10.3.276. View

13.

Zwerling A, Behr M, Verma A, Brewer T, Menzies D, Pai M . The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011; 8(3):e1001012. PMC: 3062527. DOI: 10.1371/journal.pmed.1001012. View

14.

Netea M, Van der Meer J, van Crevel R . BCG vaccination in health care providers and the protection against COVID-19. J Clin Invest. 2020; 131(2). PMC: 7810495. DOI: 10.1172/JCI145545. View

15.

Netea M, Giamarellos-Bourboulis E, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk F . Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020; 181(5):969-977. PMC: 7196902. DOI: 10.1016/j.cell.2020.04.042. View

16.

Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos D, van Crevel R . BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J Infect Dis. 2015; 212(12):1930-8. DOI: 10.1093/infdis/jiv332. View

17.

Jalalizadeh M, Buosi K, Dionato F, Col L, Giacomelli C, Ferrari K . Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response. J Intern Med. 2022; 292(4):654-666. PMC: 9347570. DOI: 10.1111/joim.13523. View

18.

Torun S, Ozkaya S, Sen N, Kanat F, Karaman I, Yosunkaya S . The Relationship between COVID-19 Severity and Bacillus Calmette-Guérin (BCG)/ exposure history in healthcare workers: a multi-center study. Pathog Glob Health. 2021; 115(6):405-411. PMC: 8146200. DOI: 10.1080/20477724.2021.1927605. View

19.

Dos Anjos L, da Costa A, Cardoso A, Guimaraes R, Rodrigues R, Ribeiro K . Efficacy and Safety of BCG Revaccination With BCG Moscow to Prevent COVID-19 Infection in Health Care Workers: A Randomized Phase II Clinical Trial. Front Immunol. 2022; 13:841868. PMC: 8981724. DOI: 10.3389/fimmu.2022.841868. View

20.

Gibellini L, De Biasi S, Paolini A, Borella R, Boraldi F, Mattioli M . Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol Med. 2020; 12(12):e13001. PMC: 7645870. DOI: 10.15252/emmm.202013001. View